β 2-adrenoceptor agonists: Current and future direction

British Journal of Pharmacology

Volumn 163, Issue 1, 2011, Pages 4-17

  Cazzola, Mario ^a   Calzetta, Luigino ^b   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

2 adrenoceptor agonists; Asthma; bronchodilators; COPD; intravenous 2 adrenoceptor agonists; long acting 2 adrenoceptor agonists; ultra long acting 2 adrenoceptor agonists

Indexed keywords

BEDORADINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARBACHOL; CARMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GSK 961081; GW 642444; INDACATEROL; ISOPRENALINE; LAS 100977; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PF 3429281; PF 610355; PLACEBO; SALBUTAMOL; SALMETEROL; SEROTONIN; TEI 3252; THRX 200495; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VILANTEROL;

ASTHMA; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FUTUROLOGY; HEART PALPITATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT OUTCOME; TREMOR;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ASTHMA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79953717418     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01216.x     Document Type: Review

References (124)

1. Agarwal SK, Marshall GD Jr, (2000). Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 105: 91-98. (Pubitemid 30059108)
2. Aldridge RE, Hancox RJ, Taylor DR, Cowan JO, Winn MC, Frampton CM, et al,. (2000). Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 161: 1459-1464. (Pubitemid 30329012)
3. Aparici M, Gõmez-Angelats M, Vilella D, Cortijo J, Morcillo EJ, Carcasona C, et al,. (2010). The in vitro pharmacological profile of LAS100977-a potent, selective and long-acting beta-2 receptor agonist [abstract]. Am J Respir Crit Care Med 181: A5675.
4. 2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3: CD001104.
5. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, (2010). Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 5: 311-318.
6. 1/2/3 adrenoceptor cAMP assays [abstract]. Am J Respir Crit Care Med 181: A4451.
7. 2- agonist (LABA) with rapid onset and long duration, on isolated large and small human airways [abstract]. Am J Respir Crit Care Med 181: A4453.
8. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al,. (2008a). Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31: 143-178.
9. 2 agonist in patients with COPD [abstract]. Proc Am Thorac Soc 5: A653.
10. 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762-770.
11. 2-adrenoceptor agonist. J Med Chem 53: 3675-3684.
12. Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, et al,. (2010). Efficacy and safety of single doses of inhaled LAS100977 in patients with persistent asthma [abstract]. Am J Respir Crit Care Med 181: A5414.
13. Bender BG, (2002). Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 109: S554-S559. (Pubitemid 34628301)
14. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 334: 53-62.
15. 2- adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett 20: 1410-1414.
16. Bouyssou T, Schnapp A, Casarosa P, Pieper MP, (2010c). Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract]. Am J Respir Crit Care Med 181: A4445.
17. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al,. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789. (Pubitemid 46294610)
18. 2- agonists in the treatment of asthma. Ther Adv Respir Dis 1: 35-46.
19. Cazzola M, Matera MG, (2008). Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155: 291-299.
20. Cazzola M, Matera MG, (2009). Emerging inhaled bronchodilators: an update. Eur Respir J 34: 757-769.
21. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23: 257-267.
22. Cazzola M, Tashkin DP, (2009). Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 6: 404-415.
23. Cazzola M, Spina D, Matera MG, (1997). The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 10: 129-144. (Pubitemid 29094856)
24. Cazzola M, Di Perna F, Noschese P, Vinciguerra A, Calderaro F, Girbino G, et al,. (1998a). Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 11: 1337-1341. (Pubitemid 28298598)
25. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, et al,. (1998b). Cardiac effects of formoterol and salmeterol in patients suffering from COPD with pre-existing cardiac arrhythmias and hypoxemia. Chest 114: 411-415. (Pubitemid 28387516)
26. 2- adrenoceptor agonists. cardiovascular safety in patients with obstructive lung disease. Drugs 65: 1595-1610. (Pubitemid 41138983)
27. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 14: 775-783. (Pubitemid 41030946)
28. Cazzola M, Andà F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, et al,. (2007). A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 20: 556-561. (Pubitemid 47077647)
29. Cazzola M, Proietto A, Matera MG, (2010a). Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 46: 139-150.
30. Cazzola M, Segreti A, Matera MG, (2010b). Novel bronchodilators in asthma. Curr Opin Pulm Med 16: 6-12.
31. Celli BR, MacNee W, (2004). Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946. (Pubitemid 38807371)
32. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest doi: 10.1378/chest.10-1830 [Epub ahead of print].
33. Charlton SJ, (2009). Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 158: 165-168.
34. 2-agonists in five major European countries, 1994-2004. J Asthma 46: 546-551.
35. Chowdhury BA, Dal Pan G, (2010). The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 362: 1169-1171.
36. Chung KF, Caramori G, Adcock IM, (2009). Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 65: 853-871.
37. 2-agonists. Thorax 51: 1051-1056. (Pubitemid 26360184)
38. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65: 473-479.
39. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, et al,. (2003). Effect of inhaled bronchodilators on inspiratory capacity and dysnoea at rest in COPD. Eur Respir J 21: 86-94.
40. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al,. (2010). Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155-162.
41. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al,. (2010). Efficacy and safety of indacaterol 150 Âμg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10: 11.
42. 2 agonist (LABA), with fast onset and long duration in the guinea-pig [abstract]. Am J Respir Crit Care Med 181: A5677.
43. Ford AJ, Hughes S, Smith C, Somers G, Ranshaw L, (2010b). The therapeutic index of vilanterol trifenatate [abstract]. Eur Respir J 24: 208s.
44. 2- adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 53: 6640-6652.
45. Haeussermann S, Acerbi A, Brand P, Poli G, Meyer T, (2006). Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD [abstract]. Eur Respir J 28: 211s.
46. Hanania NA, Dickey BF, Bond RA, (2010a). Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med 16: 1-5.
47. Hanania N, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, et al,. (2010b). Dose-related efficacy of vilanterol trifenatate in COPD [abstract]. Eur Respir J 24: 217s.
48. Hanania N, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, et al,. (2010c). Safety of vilanterol trifenatate in a COPD dose-ranging study [abstract]. Eur Respir J 24: 208s.
49. Hirst C, Calingaert B, Stanford R, Castellsague J, (2010). Use of long-acting β-agonists and inhaled steroids in asthma: meta-analysis of observational studies. J Asthma 47: 439-446.
50. 2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic β-adrenergic receptor stimulant. J Obstet Gynaecol Res 35: 405-413.
51. Johnson K, Iwaki Y, Feldman M, Matsuda K, Dunton AW, (2010). Cardiovascular effects of MN-221 (bedoradrine) administered with albuterol in dogs [abstract]. Chest 138: 174A.
52. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM, (2003). Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 40: 93-101. (Pubitemid 36417352)
53. 2- agonist, in patients with asthma: a dose-ranging study. J Asthma 45: 887-892.
54. Kanniess F, Make BJ, Petruzzelli S, (2008b). Acute effect of carmoterol, a long-acting β2-agonist, in patients with COPD [abstract]. Proc Am Thorac Soc 5: A655.
55. 2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients [abstract]. Am J Respir Crit Care Med 181: A5413.
56. 2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients [abstract]. Am J Respir Crit Care Med 181: A4447.
57. 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues. Jpn J Pharmacol 57: 175-185.
58. 2-agonists. Biol Pharm Bull 17: 1047-1052. (Pubitemid 24276338)
59. 2-selective agonist TA-2005. Mol Pharmacol 53: 128-134. (Pubitemid 28068380)
60. Kliber A, Lynd LD, Sin DD, (2010). The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res 11: 56.
61. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al,. (2010). Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J doi: 10.1183/09031936.00045810 [Epub ahead of print].
62. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma [abstract]. Eur Respir J 28: 665s.
63. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, et al,. (2008). Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 63: 103-111. (Pubitemid 350198242)
64. Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, et al,. (2010). Sustained 24-hour efficacy of once daily indacaterol (300 Âμg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther doi:10.1016/j.pupt.2010.06.005 [Epub ahead of print].
65. Lai CK, Twentyman OP, Holgate ST, (1989). The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis 140: 917-923. (Pubitemid 19259487)
66. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285: 2583-2593. (Pubitemid 32479898)
67. 2-adrenoreceptor agonist [abstract]. Eur Respir J 34: 777s.
68. Lombardi D, Cuenoud B, Krämer SD, (2009). Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 38: 533-547.
69. 2 agonist with inherent 24-hour activity, in patients with persistent asthma [abstract]. Eur Respir J 24: 1013s.
70. Lötvall J, Bakke P, Bjermer L, Steinshamn S, Crim C, Sanford L, et al,. (2010b). Safety and efficacy of fluticasone furoate/vilanterol trifenatate in COPD patients [abstract]. Eur Respir J 24: 1013s.
71. 2 adrenoreceptor agonist, PF-00610355 [abstract]. Eur Respir J 34: 344s.
72. McNamara A, Kwan K, Martin WJ, Stangeland E, Hegde S, Mammen M, et al,. (2009). Comparative preclinical efficacy of combivent and a novel, bifunctional muscarinic antagonist and β2-adrenergic agonist [abstract]. Am J Respir Crit Care Med 179: A4573.
73. van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T, (2010). Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 7: 418-427.
74. 2-agonist in patients with COPD [abstract]. Proc Am Thorac Soc 5: A961.
75. Maltais F, Beck E, Webster D, Maleki-Yazdi MR, Seibt JV, Arnoux A, et al,. (2010). Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]. Eur Respir J 24: 1014s.
76. Maspero JF, Nolte H, Chérrez-Ojeda I, (2010). Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma 47: 1106-1115.
77. Matsuda K, Iwaki Y, Feldman M, Dunton AW, (2010). Evaluation of MN-221 (bedoradrine), a novel, highly selective beta2-adrenergic receptor agonist in mild to moderate asthma via intravenous infusion [abstract]. Chest 138: 167A.
78. 2-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs [abstract]. Eur Respir J 24: 218s.
79. Moen MD, (2010). Indacaterol in chronic obstructive pulmonary disease. Drugs 70: 2269-2280.
80. 2 agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings [abstract]. Am J Respir Crit Care Med 181: A4443.
81. 2-agonist, on isolated human bronchi. Eur Respir J 29: 575-581. (Pubitemid 46372108)
82. 2- agonist carmoterol given as a 2 Âμg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma [abstract]. Eur Respir J 28: 665s.
83. National Asthma Education and Prevention Program (2007). Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120 (Suppl.): S94-S138.
84. 2-agonist, are effective for up to 24 hrs in COPD patients [abstract]. Proc Am Thorac Soc 5: A961.
85. 2-agonist, is effective in COPD patients [abstract]. Am J Respir Crit Care Med 179: A6183.
86. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, et al,. (2010). QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65: 1086-1091.
87. 2 agonists/muscarinic antagonists. Expert Opin Ther Pat 16: 1327-1331.
88. Nowak R, Iwaki Y, Matsuda K, Johnson K, Dunton AW, (2010). Reduced hospital admission and improved pulmonary function following intravenous MN-221 (bedoradrine), a novel, highly selective beta2-adrenergic receptor agonist, adjunctive to standard of care in severe acute exacerbation of asthma [abstract]. Chest 138: 66A.
89. 2-agonist, in patients with mild asthma. J Allergy Clin Immunol 124: 1217-1221.
90. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA, (2004). Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24: 86-94. (Pubitemid 39029073)
91. 2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100: 1513-1519. (Pubitemid 27425778)
92. 2 adrenoceptor agonist [abstract]. Eur Respir J 24: 218s.
93. Pearle J, Iwaki Y, Dunton AW, Kitt E, Ruby K, (2010). Intravenous MN-221, a novel, highly selective beta2-adrenergic receptor agonist, improves lung function in stable moderate to severe chronic obstructive pulmonary disease patients [abstract]. Chest 138: 487A.
94. Perry S, Woessner R, Kaiser G, Campestrini J, Picard F, Khindri S, et al,. (2010). Pharmacokinetics of indacaterol after single and multiple inhaled doses [abstract]. Am J Respir Crit Care Med 181: A4420.
95. 2 agonist [abstract]. Eur Respir J 24: 218s.
96. Poli G, Devolder A, De Backer W, Acerbi D, Nandeuil A, De Decker M, et al,. (2009). Pharmacokinetic and pharmacodynamic interaction of carmoterol and budesonide in asthmatic patients [abstract]. Am J Respir Crit Care Med 179: A2789.
97. 2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 53: 4522-4530.
98. 2-adrenergic agonist with potent and sustained in vivo bronchodilator activity in guinea pigs [abstract]. Am J Respir Crit Care Med 179: A6195.
99. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al,. (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555. (Pubitemid 47403272)
100. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA, (2009). Safety of regular use of long-acting β-agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 22: 9-19.
101. Rogers DF, (2005). Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 18: 1-8. (Pubitemid 39647747)
102. 2-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 382: 255-263.
103. 2- agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 3: 521-529.
104. Rossing TH, Make BJ, Heyman ER, (2008). Carmoterol does not induce tolerance in COPD [abstract]. Proc Am Thorac Soc 5: A962.
105. 2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol 144: 422-429. (Pubitemid 40313690)
106. Sadler BM, Dunton AW, Kitt E, Bosley J, Beaver R, (2010). Pharmacokinetics and pharmacodynamics of MN-221, a novel, highly selective beta2-adrenergic agonist for treatment of acute chronic obstructive pulmonary disease [abstract]. Chest 138: 471A.
107. Salpeter SR, Ormiston TM, Salpeter EE, (2004). Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest 125: 2309-2321. (Pubitemid 38796452)
108. 2 agonist: investigations to understand its long duration of action [abstract]. Am J Respir Crit Care Med 179: A1919.
109. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ, (2008). Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63: 592-598. (Pubitemid 351969251)
110. Standifer KM, Pitha J, Baker SP, (1989). Carbostyril-based β-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn-Schmiedebergs Arch Pharmacol 339: 129-137. (Pubitemid 19074407)
111. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 324: 70-75.
112. Sugiyama H, Nomura J, Hara T, Mitsuyama E, Igarashi J, Yamanaka Y, (2010). Pharmacological profile of a novel bronchodilator, TEI3252, as bifunctional M3 antagonist and beta2 agonist [abstract]. Am J Respir Crit Care Med 181: A4436.
113. 2 adrenoceptors. Pharmacol Toxicol Methods 58: 189-197.
114. Taylor DR, (2009). The β-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 179: 976-978.
115. Taylor DR, Sears MR, Cockcroft DW, (1996). The β-agonist controversy. Med Clin North Am 80: 719-748.
116. Timmer W, Massana Ã, Jiménez E, Seoane B, de Miquel G, Ruiz S, (2010). Single doses of LAS100977, a novel long acting β2-agonist, show high activity and long duration in healthy subjects [abstract]. Am J Respir Crit Care Med 181: A5663.
117. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, et al,. (2010). Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11: 135.
118. 2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, Vrije Universiteit, Amsterdam.
119. 2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 227: 403-409.
120. 2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther 271: 386-389. (Pubitemid 24333153)
121. 2 adrenoreceptor agonist, PF-00610355 in asthmatic patients [abstract]. Eur Respir J 34: 778s.
122. Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R, (2008). The risk of asthma mortality with inhaled long acting β-agonists. Postgrad Med J 84: 467-472.
123. Woodcock A, Nandeuil MA, Raptus H, Costantini M, Petruzzelli S, Singh D, (2009). Single dose budesonide/carmoterol fixed combination improves lung function over 24 hours in patients with moderate to severe persistent asthma [abstract]. Eur Respir J 34: 776s.
124. 2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction [abstract]. Eur Respir J 24: 1014s.